“The marketing authorisation for ledipasvir-sofosbuvir
recommends treatment for hepatitis C genotypes 1, 3 – in combination with
ribavirin – and 4”.
“Genotypes 1 and 3 hepatitis C account for the majority
of chronic hepatitis C cases in England (46% and 43%, respectively). Genotype 4
hepatitis C accounts for around 4% of cases”.
“Ledipasvir-sofosbuvir, manufactured by Gilead, is
administered orally as a single tablet – with or without ribavirin – and works
by inhibiting the replication of the hepatitis C virus. It prevents hepatitis C
virus replication by inhibiting the NS5A and NS5B proteins”.
Labels: Genotype 1, Genotype 3, genotype 4, Gilead, HCV Treatments, hepatitis C, NHS, ribavirin, sofosbuvir + ledipasvir